Literature DB >> 31002274

Association Between Secondary Prevention Medication Use and Outcomes in Frail Older Adults After Acute Myocardial Infarction.

Andrew R Zullo1,2,3,4, Amanda Mogul3,5, Katherine Corsi3,6, Nishant R Shah1,7, Sei J Lee8, James L Rudolph1,4, Wen-Chih Wu1,2,7, Ruth Dapaah-Afriyie3, Christine Berard-Collins3, Michael A Steinman8.   

Abstract

Background Secondary prevention medications are often not prescribed to frail, older adults following acute myocardial infarction, potentially because of the absence of data to support use, perceived lack of benefit, and concern over possible harms. We examined the effect of using more guideline-recommended medications after myocardial infarction on mortality, rehospitalization, and functional decline in the frailest and oldest segment of the US population-long-stay nursing home residents. Methods and Results We conducted a retrospective cohort study of nursing home residents aged ≥65 years using 2007 to 2010 national US Minimum Data Set clinical assessment data and Medicare claims. Exposure was the number of secondary prevention medications (antiplatelets, β-blockers, statins, and renin-angiotensin-aldosterone system inhibitors) initiated after myocardial infarction. Outcomes were 90-day death, rehospitalization, and functional decline. We compared outcomes for new users of 2 versus 1 and 3 or 4 versus 1 medications using the inverse probability of treatment-weighted odds ratios with 95% CI. The cohort comprised 4787 residents, with a total of 509 death, 820 functional decline, and 1226 rehospitalization events. Compared with individuals who initiated 1 medication, mortality odds ratios were 0.98 (95% CI, 0.79-1.22) and 0.74 (95% CI, 0.57-0.97) for users of 2 and 3 or 4 medications, respectively. Rehospitalization odds ratios were 1.00 (95% CI, 0.85-1.17) for 2 and 0.97 (95% CI, 0.8-1.17) for 3 or 4 medications. Functional decline odds ratios were 1.04 (95% CI, 0.85-1.28) for 2 and 1.12 (95% CI, 0.89-1.40) for 3 or 4 medications. In a stability analysis excluding antiplatelet drugs from the exposure definition, more medication use was associated with functional decline. Conclusions Use of more guideline-recommended medications after myocardial infarction was associated with decreased mortality in older, predominantly frail adults, but no difference in rehospitalization. Results for functional decline from the main and stability analyses were discordant and did not rule out an increased risk associated with more medication use.

Entities:  

Keywords:  geriatrics; mortality; myocardial infarction; nursing homes; pharmacoepidemiology

Year:  2019        PMID: 31002274      PMCID: PMC6481629          DOI: 10.1161/CIRCOUTCOMES.118.004942

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  36 in total

1.  Scaling ADLs within the MDS.

Authors:  J N Morris; B E Fries; S A Morris
Journal:  J Gerontol A Biol Sci Med Sci       Date:  1999-11       Impact factor: 6.053

Review 2.  Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care.

Authors:  Linda P Fried; Luigi Ferrucci; Jonathan Darer; Jeff D Williamson; Gerard Anderson
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2004-03       Impact factor: 6.053

3.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Patrick T O'Gara; Frederick G Kushner; Deborah D Ascheim; Donald E Casey; Mina K Chung; James A de Lemos; Steven M Ettinger; James C Fang; Francis M Fesmire; Barry A Franklin; Christopher B Granger; Harlan M Krumholz; Jane A Linderbaum; David A Morrow; L Kristin Newby; Joseph P Ornato; Narith Ou; Martha J Radford; Jacqueline E Tamis-Holland; Carl L Tommaso; Cynthia M Tracy; Y Joseph Woo; David X Zhao
Journal:  J Am Coll Cardiol       Date:  2012-12-17       Impact factor: 24.094

4.  Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available.

Authors:  Miguel A Hernán; James M Robins
Journal:  Am J Epidemiol       Date:  2016-03-18       Impact factor: 4.897

5.  beta Blockade after myocardial infarction: systematic review and meta regression analysis.

Authors:  N Freemantle; J Cleland; P Young; J Mason; J Harrison
Journal:  BMJ       Date:  1999-06-26

6.  Beta-Blocker Use in U.S. Nursing Home Residents After Myocardial Infarction: A National Study.

Authors:  Andrew R Zullo; Yoojin Lee; Lori A Daiello; Vincent Mor; W John Boscardin; David D Dore; Yinghui Miao; Kathy Z Fung; Kiya D R Komaiko; Michael A Steinman
Journal:  J Am Geriatr Soc       Date:  2016-11-15       Impact factor: 5.562

7.  Reducing inappropriate polypharmacy: the process of deprescribing.

Authors:  Ian A Scott; Sarah N Hilmer; Emily Reeve; Kathleen Potter; David Le Couteur; Deborah Rigby; Danijela Gnjidic; Christopher B Del Mar; Elizabeth E Roughead; Amy Page; Jesse Jansen; Jennifer H Martin
Journal:  JAMA Intern Med       Date:  2015-05       Impact factor: 21.873

8.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

9.  Individualizing Prevention for Older Adults.

Authors:  Sei J Lee; Christine M Kim
Journal:  J Am Geriatr Soc       Date:  2017-11-20       Impact factor: 5.562

Review 10.  Screening for Medication Appropriateness in Older Adults.

Authors:  Andrew R Zullo; Shelly L Gray; Holly M Holmes; Zachary A Marcum
Journal:  Clin Geriatr Med       Date:  2017-10-14       Impact factor: 3.529

View more
  4 in total

1.  Effects of Statins for Secondary Prevention on Functioning and Other Outcomes Among Nursing Home Residents.

Authors:  Andrew R Zullo; Richard Ofori-Asenso; Marci Wood; Allison Zuern; Yoojin Lee; Wen-Chih Wu; James L Rudolph; Danny Liew; Michael A Steinman
Journal:  J Am Med Dir Assoc       Date:  2020-03-03       Impact factor: 4.669

2.  Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.

Authors:  Tianyu Li; Xiaofang Tang; Ying Song; Yi Yao; Xueyan Zhao; Zhan Gao; Yuejin Yang; Runlin Gao; Bo Xu; Jinqing Yuan
Journal:  Glob Heart       Date:  2021-12-27

3.  Adherence to recommendations for secondary prevention medications after myocardial infarction in Estonia: comparison of real-world data from 2004 to 2005 and 2017 to 2018.

Authors:  Piret Lõiveke; Toomas Marandi; Tiia Ainla; Krista Fischer; Jaan Eha
Journal:  BMC Cardiovasc Disord       Date:  2021-10-20       Impact factor: 2.298

4.  Comparative Effectiveness of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in Older Nursing Home Residents After Myocardial Infarction: A Retrospective Cohort Study.

Authors:  Andrew R Zullo; Melissa R Riester; Sebhat Erqou; Wen-Chih Wu; James L Rudolph; Michael A Steinman
Journal:  Drugs Aging       Date:  2020-10       Impact factor: 3.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.